KYMR Kymera Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1815442 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY133.8%
TTM net income YoY-18.4%
TTM EPS YoY-1.1%
Revenue 3-yr CAGR29.7%
Net income 3-yr CAGR—
Margins
Gross margin0.0%
Operating margin-396.0%
Net margin-341.8%
FCF margin-282.6%
EBITDA margin-388.9%
Returns
ROE-27.3%
ROA-24.4%
ROIC (approx.)-30.8%
Asset turnover0.07x
Leverage & solvency
Liabilities / assets8.6%
Debt / equity0.00x
Current ratio11.13x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-4.3%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $39.21M | $47.07M | $78.59M | $46.83M | $72.83M |
| Cost of revenue | $39.21M | $47.07M | $78.59M | $46.83M | — |
| Gross profit | $0 | $0 | $0 | $0 | — |
| R&D expense | $316.57M | $240.25M | $189.08M | $164.25M | $137.02M |
| SG&A expense | $68.19M | $63.53M | $55.04M | $43.83M | $36.34M |
| Operating income | -$349.40M | -$261.63M | -$165.53M | -$161.26M | -$100.53M |
| Pretax income | -$311.35M | — | — | — | — |
| Income tax | $0 | — | — | $0 | $0 |
| Net income | -$311.35M | -$223.86M | -$146.96M | -$154.81M | -$100.22M |
| EBITDA | -$341.09M | -$254.26M | -$161.97M | -$158.28M | -$98.13M |
| EPS (basic) | -3.69 | -2.98 | -2.52 | -2.87 | -2.09 |
| EPS (diluted) | -3.69 | -2.98 | -2.52 | -2.87 | -2.09 |
| Weighted avg. shares (diluted) | 84.49M | 75.04M | 58.37M | 53.93M | 47.99M |
| Balance sheet | |||||
| Cash & equivalents | $357.01M | $120.26M | $109.97M | $68.39M | $47.98M |
| Short-term investments | $491.26M | $368.49M | $264.92M | $338.77M | $394.44M |
| Receivables | $0 | $0 | $15.00M | $0 | — |
| Current assets | $871.21M | $510.27M | $405.32M | $419.42M | $451.27M |
| PP&E, net | $43.17M | $50.46M | $48.13M | $13.33M | $11.88M |
| Total assets | $1.74B | $978.03M | $575.76M | $603.13M | $605.90M |
| Current liabilities | $83.21M | $67.77M | $85.69M | $71.34M | $92.54M |
| Total liabilities | $163.15M | $142.42M | $180.79M | $112.98M | $146.27M |
| Shareholders' equity | $1.58B | $835.62M | $394.97M | $490.15M | $459.64M |
| Shares outstanding | 81.32M | 64.89M | 55.59M | 55.04M | 51.54M |
| Cash flow statement | |||||
| Operating cash flow | -$232.89M | -$194.50M | -$102.83M | -$153.09M | -$128.95M |
| Capital expenditure | $1.45M | $12.84M | $34.48M | $2.84M | $1.60M |
| Free cash flow | -$234.34M | -$207.34M | -$137.31M | -$155.92M | -$130.54M |
| Investing cash flow | -$521.06M | -$404.08M | $139.89M | $20.52M | -$99.83M |
| Financing cash flow | $990.71M | $608.85M | $4.19M | $153.00M | $250.28M |
| Depreciation & amortization | $8.31M | $7.37M | $3.56M | $2.98M | $2.40M |
| Stock-based compensation | $59.90M | $55.01M | $43.12M | $35.48M | $24.97M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.